Evidence map›Paper›PMID 26154925›Full record

ArticleKidney international2015

Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults.

Pranav S Garimella, Mary L Biggs, Ronit Katz, Joachim H Ix, Michael R Bennett, Prasad Devarajan, Bryan R Kestenbaum, David S Siscovick, Majken K Jensen, Michael G Shlipak and 2 more

Open access · greenAbstract read
In one paragraph

Article in Kidney international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017
    Trial
  5. Review
  6. Endocrine regulation of uromodulin in aging.Frontiers in endocrinology · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Uromodulin and progression of IgA nephropathy.Clinical kidney journal · 2024
    Article
  16. Uromodulin biology.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Review
  17. The role of uromodulin in cardiovascular disease: a review.Frontiers in cardiovascular medicine · 2024
    Review
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Pranav S GarimellaDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
Mary L BiggsDepartment of Biostatistics, University of Washington, Seattle, Washington, USA.
Ronit KatzKidney Research Institute, University of Washington, Seattle, Washington, USA.
Joachim H IxDivision of Nephrology, Universty of California, San Diego, San Diego, California, USA.
Michael R BennettDepartment of Nephrology and Hypertension, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, Ohio, USA.
Prasad DevarajanDepartment of Nephrology and Hypertension, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, Ohio, USA.
Bryan R KestenbaumKidney Research Institute and Harborview Medical Center, University of Washington, Seattle, Washington, USA.
David S SiscovickNew York Academy of Medicine, New York, New York, USA.
Majken K JensenDepartment of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA.
Michael G ShlipakDivision of General Internal Medicine, University of California, San Francisco, San Francisco, California, USA.
Paulo H M ChavesHerbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
Mark J SarnakDivision of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.
Cincinnati Children's Hospital Medical Center · USTufts Medical Center · USUniversity of Washington · USFlorida International University · USHarborview Medical Center · USHarvard University · USNew York Academy of Medicine · USUniversity of California, San Diego · USUniversity of California, San Francisco · US

Funding

Exceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5M
Proteomics CoreP50DK096418 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD · 2012 to 2021
$8.4M
The Aging Kidney: Chronic Injury, Impaired Functions and Clinical OutcomesR01AG027002 · NIA · TUFTS MEDICAL CENTER · PI PARIKH, SAMIR M, SARNAK, MARK J · 2005 to 2022
$7.3M
Kidney Tubular Damage and Dysfunction Identify a Novel Axis of Chronic Kidney DiseaseR01DK098234 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI IX, JOACHIM H, SHLIPAK, MICHAEL G · 2014 to 2023
$5.6M
CHS Events Follow-up StudyU01HL080295 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 2005 to 2008
$4.6M
Epidemiology, Clinical Trials and Outcomes Research In NephrologyT32DK007777 · NIDDK · TUFTS MEDICAL CENTER · PI SARNAK, MARK J · 1999 to 2020
$4.1M
CORONARY HEART DISEASE &STROKE IN PEOPLE AGED 65-84N01HC085081 · HC · JOHNS HOPKINS UNIVERSITY · PI FRIED, LINDA P · 1988 to 2000
–
CORONARY HEART DISEASE AND STROKE IN PEOPLE AGED 65-84N01HC085082 · HC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KULLER, LEWIS H · 1988 to 2000
–
CORONARY HEART DISEASE &STROKE IN PEOPLE AGED 65-84N01HC085083 · HC · UNIVERSITY OF CALIFORNIA DAVIS · PI ROBBINS, JOHN A · 1988 to 1999
–
MRI READING CENTER FOR THE CARDIOVASCULAR HEALTH STUDYN01HC015103 · HC · JOHNS HOPKINS UNIVERSITY · PI BEAUCHAMP, NORMAN J · 1991 to 1998
–
CORONARY HEART DISEASE AND STROKE IN PEOPLE AGED 65-84N01HC085085 · HC · NEW ENGLAND DEACONESS HOSPITAL · PI O'LEARY, DANIEL · 1988 to 1993
–
CENTRAL BLOOD ANALYSIS LABORATORY FOR CHSN01HC085086 · HC · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI TRACY, RUSSELL P · 1988 to 2000
–
NHLBI NIH HHS HHSN268200800007CNHLBI NIH HHS HHSN268201200036CNHLBI NIH HHS N01 HC055222NHLBI NIH HHS N01 HC075150NHLBI NIH HHS N01 HC085079NHLBI NIH HHS N01 HC085086NHLBI NIH HHS N01HC-15103NHLBI NIH HHS N01HC-35129NHLBI NIH HHS N01HC-54133NHLBI NIH HHS N01HC-55222NHLBI NIH HHS N01HC-75150NHLBI NIH HHS N01HC-85079NHLBI NIH HHS N01HC-85080NHLBI NIH HHS N01HC-85081NHLBI NIH HHS N01HC-85082NHLBI NIH HHS N01HC-85083NHLBI NIH HHS N01HC-85084NHLBI NIH HHS N01HC-85085NHLBI NIH HHS N01HC-85086NHLBI NIH HHS N01-HC85239NHLBI NIH HHS U01 HL080295NIA NIH HHS R01AG023629NIA NIH HHS R01 AG027002NIA NIH HHS R01AG027002NIDDK NIH HHS 5 T32 DK007777-13NIDDK NIH HHS P50 DK096418NIDDK NIH HHS R01 DK098234NIDDK NIH HHS T32 DK007777
6 · The paper itself

Abstract

Urinary uromodulin (uUMOD) is the most common secreted tubular protein in healthy adults. However, the relationship between uUMOD and clinical outcomes is still unclear. Here we measured uUMOD in 192 participants of the Cardiovascular Health Study with over a 30% decline in estimated glomerular filtration rate (eGFR) over 9 years, 54 with incident end-stage renal disease (ESRD), and in a random subcohort of 958 participants. The association of uUMOD with eGFR decline was evaluated using logistic regression and with incident ESRD, cardiovascular disease, heart failure, and mortality using Cox proportional regression. Mean age was 78 years and median uUMOD was 25.8 μg/ml. In a case-control study evaluating eGFR decline (192 cases and 231 controls), each 1-s.d. higher uUMOD was associated with a 23% lower odds of eGFR decline (odds ratio 0.77 (95% CI 0.62-0.96)) and a 10% lower risk of mortality (hazard ratio 0.90 (95% CI 0.83-0.98)) after adjusting for demographics, eGFR, albumin/creatinine ratio, and other risk factors. There was no risk association of uUMOD with ESRD, cardiovascular disease, or heart failure after multivariable adjustment. Thus, low uUMOD levels may identify persons at risk of progressive kidney disease and mortality above and beyond established markers of kidney disease, namely eGFR and the albumin/creatinine ratio. Future studies need to confirm these results and evaluate whether uUMOD is a marker of tubular health and/or whether it plays a causal role in preserving kidney function.

Indexed as

Glomerular Filtration RateAgedAged, 80 and overAlbuminuriaBiomarkersCardiovascular DiseasesCase-Control StudiesCreatinineDisease ProgressionFemaleHeart FailureHumansIncidenceKidney Failure, ChronicMaleProportional Hazards ModelsBiomarkersCreatinineUromodulin

Identifiers

PMID26154925
PMCPMC4653069
OpenAlexW1567241254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.